IFNL3 and Cirrhosis: With respect to the prediction of the efficacy of telaprevir-based triple therapy, other investigators have already reported that amino acid substitution at core 70, IL28B SNP, cirrhosis, alpha-fetoprotein (AFP) level, and prior treatment response are significant pretreatment predictive factors of SVR [6, 18–20].